Arteris (AIP) director’s trust sells 70,000 shares under Rule 10b5-1 plan

Q: What insider activity did Arteris (AIP) disclose in this Form 4?

Arteris disclosed that director Saiyed Atiq Raza , through a family revocable trust, reported open‑market sales of 70,000 shares of Arteris common stock on June 1, 2026 under a pre‑arranged Rule 10b5‑1 trading plan.

Q: How many Arteris (AIP) shares did the trust sell and at what prices?

The revocable trust associated with Saiyed Atiq Raza sold 70,000 Arteris shares in two blocks: 3,600 shares at a weighted average of $36.4503 and 66,400 shares at a weighted average of $35.9922, each executed across multiple individual trades.

Q: Who actually holds the Arteris (AIP) shares involved in these Form 4 sales?

The sold shares were held by the Saiyed Atiq Raza and Nandini Saraiya 2012 Revocable Trust . The filing notes that Raza serves as trustee of this trust, so the sales are attributed to the trust rather than to direct personal holdings.

Q: What Arteris (AIP) holdings does director Saiyed Atiq Raza report after these transactions?

After the reported transactions, the Form 4 shows 20,839 shares of Arteris common stock held directly by Saiyed Atiq Raza. The filing also discloses continuing indirect ownership through the revocable trust, with share counts detailed in the transaction table.

Q: How are the Arteris (AIP) sale prices described in the Form 4 filing?

Each sales line reports a weighted average sale price . Footnotes explain that shares were sold in multiple transactions within price ranges of $35.34–$36.33 and $36.34–$36.56, and that full trade‑by‑trade details are available upon request.

Filing Impact

(Very High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Arteris, Inc. director Saiyed Atiq Raza reported open‑market sales of Arteris common stock made through a family trust under a pre‑arranged Rule 10b5‑1 trading plan. On June 1, 2026, the Saiyed Atiq Raza and Nandini Saraiya 2012 Revocable Trust sold 70,000 shares in two transactions at weighted average prices of about $35.99 and $36.45 per share.

These transactions were executed in multiple trades within stated price ranges, and the filing notes that detailed trade breakdowns are available on request. After the reported activity, Raza also shows a separate direct holding of 20,839 Arteris shares.

Insider Trade Summary 10b5-1

Net Seller: 70,000 shares ($2,521,103)

Net Sell 3 txns

Insider RAZA SAIYED ATIQ

Role null

Sold 70,000 shs ($2.52M)

Type	Security	Shares	Price	Value
Sale	Common Stock	66,400	$35.9922	$2.39M
Sale	Common Stock	3,600	$36.4503	$131K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 143,600 shares (Indirect, By Saiyed Atiq Raza and Nandini Saraiya 2012 Revocable Trust dtd 11/26/2012); Common Stock — 20,839 shares (Direct, null)

Footnotes (1)

Transaction made pursuant to a 10b5-1 trading plan that was adopted by the Reporting Person on November 7, 2025. The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $35.34 to $36.33 inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The shares are held by Saiyed Atiq Raza and Nandini Saraiya 2012 Revocable Trust for which the Reporting Person serves as trustee. The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $36.34 to $36.56 inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Key Figures

Total shares sold: 70,000 shares First block sold: 3,600 shares at $36.4503 Second block sold: 66,400 shares at $35.9922 +4 more

7 metrics

Total shares sold 70,000 shares Open-market sales by revocable trust on June 1, 2026

First block sold 3,600 shares at $36.4503 Weighted average sale price, multiple trades

Second block sold 66,400 shares at $35.9922 Weighted average sale price, multiple trades

Direct holdings after transaction 20,839 shares Common stock held directly by Raza following reported transactions

Trading plan adoption date November 7, 2025 Date Rule 10b5-1 plan was adopted

Lower sale price range $35.34–$36.33 Range for one weighted average sale block

Higher sale price range $36.34–$36.56 Range for second weighted average sale block

Key Terms

Rule 10b5-1 trading plan, weighted average sale price, Revocable Trust, open-market sale

4 terms

Rule 10b5-1 trading plan regulatory

"Transaction made pursuant to a 10b5-1 trading plan that was adopted by the Reporting Person..."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average sale price financial

"The price reported in Column 4 is a weighted average sale price."

Revocable Trust financial

"The shares are held by Saiyed Atiq Raza and Nandini Saraiya 2012 Revocable Trust..."

A revocable trust is a legal arrangement where the person who creates it keeps control and can change or cancel the trust at any time, while naming who will manage and receive the assets later. Think of it like a flexible folder for your investments and property that can be relabeled or reworked as circumstances change; it matters to investors because it determines how ownership is recorded, how easily assets transfer on incapacity or death, and whether holdings bypass public probate proceedings.

open-market sale market

"transaction_action: open-market sale"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

06/03/2026 - 05:24 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

RAZA SAIYED ATIQ

(Last)

(First)

(Middle)

C/O ARTERIS, INC.

900 E. HAMILTON AVE., SUITE 300

(Street)

CAMPBELL

CALIFORNIA

95008

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Arteris, Inc. [ AIP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/01/2026		S⁽¹⁾		66,400	D	$35.9922⁽²⁾	143,600	I	By Saiyed Atiq Raza and Nandini Saraiya 2012 Revocable Trust dtd 11/26/2012⁽³⁾
Common Stock	06/01/2026		S⁽¹⁾		3,600	D	$36.4503⁽⁴⁾	140,000	I	By Saiyed Atiq Raza and Nandini Saraiya 2012 Revocable Trust dtd 11/26/2012
Common Stock								20,839	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Transaction made pursuant to a 10b5-1 trading plan that was adopted by the Reporting Person on November 7, 2025.

2. The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $35.34 to $36.33 inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. The shares are held by Saiyed Atiq Raza and Nandini Saraiya 2012 Revocable Trust for which the Reporting Person serves as trustee.

4. The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $36.34 to $36.56 inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

	/s/ Paul Alpern, as Attorney-in-Fact for S. Atiq Raza	06/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider activity did Arteris (AIP) disclose in this Form 4?

Arteris disclosed that director Saiyed Atiq Raza, through a family revocable trust, reported open‑market sales of 70,000 shares of Arteris common stock on June 1, 2026 under a pre‑arranged Rule 10b5‑1 trading plan.

How many Arteris (AIP) shares did the trust sell and at what prices?

The revocable trust associated with Saiyed Atiq Raza sold 70,000 Arteris shares in two blocks: 3,600 shares at a weighted average of $36.4503 and 66,400 shares at a weighted average of $35.9922, each executed across multiple individual trades.

Were the Arteris (AIP) insider sales made under a Rule 10b5-1 plan?

Yes. A footnote states the transactions were made pursuant to a Rule 10b5‑1 trading plan adopted on November 7, 2025. Such plans are established in advance, which generally indicates the sales were pre‑scheduled rather than timed reactively to short‑term news.

Who actually holds the Arteris (AIP) shares involved in these Form 4 sales?

The sold shares were held by the Saiyed Atiq Raza and Nandini Saraiya 2012 Revocable Trust. The filing notes that Raza serves as trustee of this trust, so the sales are attributed to the trust rather than to direct personal holdings.

What Arteris (AIP) holdings does director Saiyed Atiq Raza report after these transactions?

After the reported transactions, the Form 4 shows 20,839 shares of Arteris common stock held directly by Saiyed Atiq Raza. The filing also discloses continuing indirect ownership through the revocable trust, with share counts detailed in the transaction table.

How are the Arteris (AIP) sale prices described in the Form 4 filing?

Each sales line reports a weighted average sale price. Footnotes explain that shares were sold in multiple transactions within price ranges of $35.34–$36.33 and $36.34–$36.56, and that full trade‑by‑trade details are available upon request.